Decheng Capital LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0002010850
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2023 · 24 positions · Total reported value $357.92M · Top-10 concentration 84.6% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 35.7% · 0 new · 2 cut · 3 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -3.5% · vs SPY -5.6% · Prev Value $731.75M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -13.4% · vs SPY -15.6% · Latest Value $685.07M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q4 2023 13F filing, Decheng Capital LLC disclosed 24 equity positions with a combined reported value of $357.92M. The filing implies a focused portfolio: its ten largest positions account for 84.6% of reported value. HoldingsHub classifies the profile as Small / Focused / High Turnover.
The largest disclosed positions as of Q4 2023 were ALPN ($135.01M), ZNTL ($31.81M), PACB ($28.84M). By sector, the heaviest allocations are Health Care 34.4%, Industrials 13.7%.
Versus the prior quarter, Decheng Capital LLC opened 0 new positions, trimmed 2 and fully exited 3, a turnover rate of 35.7% of positions.
The largest new positions opened in Q4 2023 were ALPN ($135.01M), ZNTL ($31.81M), PACB ($28.84M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2023)
- ALPN ALPINE IMMUNE SCIENCES INC · $135.01M
- ZNTL ZENTALIS PHARMACEUTICALS INC · $31.81M
- PACB PACIFIC BIOSCIENCES CALIF IN · $28.84M
- TXG 10X GENOMICS INC · $20.12M
- IMGN IMMUNOGEN INC · $19.57M
- RCUS ARCUS BIOSCIENCES INC · $16.61M
- KRTX KARUNA THERAPEUTICS INC · $14.88M
- ROIV ROIVANT SCIENCES LTD · $14.37M
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest Decheng Capital LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Decheng Capital LLC, based in Menlo Park, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 14 positions worth $731.75M in total. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).
Firm Snapshot
- Headquarters: MENLO PARK, CA, United States
- SEC registration: 801-118587 (status: Approved), registered 2020-04-30
- Regulatory AUM (Form ADV): $2.73B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 8 private funds, of which 1 hedge funds
- Website: decheng.com
Portfolio Structure
- 14 positions · $731.75M reported value (Q2 2026)
- Top 10 holdings = 98.1% of reported value
- Largest position: CGON (CG ONCOLOGY INC) at 61.9%
- Average position size: $52.27M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 1 new, 3 reduced, 1 exited
- 10 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
7.08M | $135.01M | 37.72% | New | |
| 2 |
|
2.10M | $31.81M | 8.89% | New | |
| 3 |
|
2.94M | $28.84M | 8.06% | New | |
| 4 |
|
359.55K | $20.12M | 5.62% | New | |
| 5 |
|
659.93K | $19.57M | 5.47% | New | |
| 6 |
|
869.79K | $16.61M | 4.64% | New | |
| 7 |
|
47.00K | $14.88M | 4.16% | New | |
| 8 |
|
1.28M | $14.37M | 4.01% | New | |
| 9 |
|
80.86K | $11.26M | 3.15% | New | |
| 10 |
|
27.43K | $10.43M | 2.92% | New | |
| 11 |
|
1.37M | $10.23M | 2.86% | New | |
| 12 |
|
65.77K | $8.16M | 2.28% | New | |
| 13 |
|
850.00K | $7.76M | 2.17% | New | |
| 14 |
|
92.20K | $5.72M | 1.60% | New | |
| 15 |
|
714.28K | $4.64M | 1.29% | New | |
| 16 |
|
515.55K | $4.57M | 1.28% | New | |
| 17 |
|
4.96M | $4.45M | 1.24% | New | |
| 18 |
|
4.45M | $3.22M | 0.90% | New | |
| 19 |
|
46.26K | $1.65M | 0.46% | New | |
| 20 |
|
8.98M | $1.46M | 0.41% | New | |
| 21 |
|
555.55K | $1.24M | 0.35% | New | |
| 22 |
|
526.33K | $1.06M | 0.30% | New | |
| 23 |
|
326.81K | $588.26K | 0.16% | New | |
| 24 |
|
103.60K | $284.91K | 0.08% | New | |
FAQ
What did Decheng Capital LLC buy in 2023-Q4?
In its 2023-Q4 13F filing, Decheng Capital LLC reported 24 equity positions worth $357.92M in aggregate; its largest disclosed positions were ALPN ($135.01M), ZNTL ($31.81M), PACB ($28.84M).
How large is Decheng Capital LLC's portfolio?
Decheng Capital LLC reported $357.92M of long equity holdings across 24 positions as of 2023-Q4. Top-10 holdings account for 84.6% of reported value.
What is Decheng Capital LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.